https://assets.capyfin.com/instruments/678fdc13234e27009c5d57fd.png avatar
Medtronic
🇮🇪 NYSE:MDT
View Company
OverviewEarningsDividends
•
Jan 24, 2020

Medtronic Q3 2020 Earnings Report

Medtronic's financial performance was reported for Q3 2020, with revenue and EPS increases, along with raised full-year EPS guidance.

Key Takeaways

Medtronic reported a 2.3% increase in revenue to $7.7 billion and a 51% increase in GAAP diluted EPS to $1.42. The company also raised its full-year EPS guidance.

Revenue increased by 2.3% as reported and 2.6% organically, reaching $7.7 billion.

GAAP diluted EPS rose by 51% to $1.42, while non-GAAP diluted EPS increased by 12% to $1.44.

Cash flow from operations grew by 17% to $2.4 billion, and free cash flow increased by 21% to $2.1 billion.

The company raised its full-year EPS guidance, indicating positive expectations for future performance.

Total Revenue
$7.72B
Previous year: $7.55B
+2.3%
EPS
$1.44
Previous year: $1.29
+11.6%
Total Organic Revenue Growth
2.6%
Gross Profit
$5.32B
Previous year: $5.28B
+0.7%
Cash and Equivalents
$3.71B
Previous year: $3.7B
+0.2%
Free Cash Flow
$2.11B
Previous year: $1.75B
+20.6%
Total Assets
$92.8B
Previous year: $88.7B
+4.6%

Medtronic

Medtronic

Medtronic Revenue by Segment

Medtronic Revenue by Geographic Location

Forward Guidance

The company issued fourth quarter revenue growth guidance and raised its full year EPS guidance for fiscal year 2020.The company indicated that it is comfortable with current Street consensus calling for fourth quarter organic revenue growth of approximately 4.5 percent and EPS of $1.64, excluding any impact from COVID-19.

Positive Outlook

  • Company is comfortable with current Street consensus calling for fourth quarter organic revenue growth of approximately 4.5 percent.
  • Company is comfortable with current Street consensus calling for EPS of $1.64, excluding any impact from COVID-19.
  • Company increased its fiscal year 2020 diluted non-GAAP EPS guidance from the prior range of $5.57 to $5.63 to a new range of $5.63 to $5.65.
  • Implies fourth quarter diluted non-GAAP EPS in the range of $1.62 to $1.64.
  • Top-line growth acceleration is on track as we begin to realize the benefits of new product launches and put the challenges of the third quarter behind us.

Challenges Ahead

  • Fourth quarter revenue growth would be negatively affected by 0.8 to 1.4 percent if current exchange rates hold.
  • Includes an estimated 7 cent negative impact from foreign exchange based on current rates and excluding any impact from COVID-19.
  • Includes an estimated 3 cent negative impact from foreign exchange based on current rates and excluding any impact from COVID-19
  • COVID-19 is expected to negatively affect the company’s fourth quarter financial results
  • The duration and magnitude of the impact from COVID-19 are difficult to quantify at this time.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Medtronic